Using CD133 as a colon cancer stem cell marker has continued to be controversial as some studies have found other markers, such as CD44, EpCAM (CD326), and CD166, to be much more robust at identifying colorectal CSCs [98, 99]. This evidence concerns the gene EPCAM and malignant colon neoplasm.